AI-based retinal disease detection software introduced at TB screening sites

WISKY, an artificial intelligence-based retinal disease detection software, is being introduced to TB screening sites.

Optical device maker ARK said Wednesday that it has signed an agreement with the Korean National Tuberculosis Association (KNTA) to prevent diabetes and hypertension complications.

As part of the agreement, ARK's AI-based retinal disease detection software WISKY will be installed at TB screening sites and nine KNTA-affiliated clinics nationwide to be utilized for screening.

WISKY is an AI-powered blindness diagnosis platform that reads and provides results for diabetic retinopathy, macular degeneration, and glaucoma, the three major diseases that cause blindness. When an image with a fundus camera is linked to the WISKY program, an AI algorithm analyzes the image and detects the disease. The retina images can be read within three to five seconds with a single click, helping doctors make a quick and effective diagnosis.

In addition, the diagnosis results can be explained to patients easily and in detail, as each lesion area is marked with a different color, and an image-based reading report is provided so that patients can quickly identify the lesion area.

In addition to WILKY, the collaboration will develop various chronic disease management programs, including heart, kidney, and dementia programs, to help patients receive better care.

“Through WISKY, we will be able to grow into a company that leads the way in preventing chronic diseases and helps the country's finances,” ARK CEO Kim Hyung-hoe said.